<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151814</url>
  </required_header>
  <id_info>
    <org_study_id>CS0866-A-U102</org_study_id>
    <nct_id>NCT00151814</nct_id>
  </id_info>
  <brief_title>Olmesartan Pediatric Pharmacokinetic (PK) Study</brief_title>
  <official_title>An Open-label Study of the Single-dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with
      hypertension in ages 12 months - 16 years
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)</measure>
    <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For Olmesartan, Area Under the Concentration-time Curve From the Time of the Dose to Infinity</measure>
    <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For Olmesartan, the Elimination Constant Rate</measure>
    <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For Olmesartan, the Maximum Plasma Concentration Over the Entire Sampling Phase</measure>
    <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Foe Olmesartan, the Time of Maximum Plasma Concentration</measure>
    <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For Olmesartan, the Elimination Half-life of the Drug in Plasma</measure>
    <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For Olmesartan, the Apparent Oral Clearance</measure>
    <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For Olmesartan, the Apparent Oral Volume of Distribution</measure>
    <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Olmesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children less than 6 years old received 0.3 mg/kg. Children 6 years old or older received 40 mg, if they weighed 35 kg or more; 20 mg if they weighed less than 35 kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <description>Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.</description>
    <arm_group_label>Olmesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 12 months to 16 years inclusive

          -  Signed parental/guardian informed consent and assent from the subject

          -  Current treatment for hypertension, or, if not currently treated for hypertension,
             systolic blood pressure (SBP) greater than or equal to 95th percentile for gender and
             height-for-age, or, if not currently treated for hypertension, systolic blood pressure
             or diastolic blood pressure greater than or equal to 90th percentile for gender and
             height-for-age and diabetic or having a family history of hypertension

          -  Glomerular filtration rate (GFR) greater than or equal to 30 mL/min/1.73 m2, estimated
             using the Schwartz equation

          -  Sexually active females of child-bearing potential must be practicing an acceptable
             method of birth control

          -  Negative serum beta-human chorionic gonadotropin at screening and at admission (female
             of child-bearing potential only)

        Exclusion Criteria:

          -  Clinically significant cardiac, gastrointestinal, hematologic, hepatic or
             hepatobiliary, neurologic, or pulmonary (except asthma) disorder

          -  History of severe or symptomatic hypertension associated with stroke, seizures,
             encephalopathy, or other significant neurologic findings within 1 year prior to
             screening

          -  Current treatment with more than 2 antihypertensive medications

          -  Secondary hypertension from uncorrected coarctation of the aorta, bilateral renal
             artery stenosis, or unilateral renal artery stenosis in a single kidney

          -  Serum albumin &lt; 2.5 g/dL

          -  Major organ or bone marrow transplantation except for prior kidney transplantation of
             at least 6 months and with stable renal function meeting the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <results_first_submitted>March 19, 2010</results_first_submitted>
  <results_first_submitted_qc>March 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2010</results_first_posted>
  <disposition_first_submitted>December 5, 2008</disposition_first_submitted>
  <disposition_first_submitted_qc>October 5, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 7, 2009</disposition_first_posted>
  <last_update_submitted>April 12, 2010</last_update_submitted>
  <last_update_submitted_qc>April 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Michael Melino, PhD</name_title>
    <organization>Daiichi Sankyo</organization>
  </responsible_party>
  <keyword>Olmesartan PK in children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was from September 2005 to February 2008. This period lasted for this length of time because of difficulties in recruiting participants. Children from 12 months old to 16 years old were to be enrolled.</recruitment_details>
      <pre_assignment_details>The 2-5 years old cohort had only 4 participants and their data were not sufficient for meaningful analysis. No participants in the 12-23 month old category were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olmesartan Group - 2 to 5 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
        <group group_id="P2">
          <title>Olmesartan Group - 6 to 12 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
        <group group_id="P3">
          <title>Olmesartan Group - 13 to 16 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olmesartan Group - 2 to 5 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
        <group group_id="B2">
          <title>Olmesartan Group - 6 to 12 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
        <group group_id="B3">
          <title>Olmesartan Group - 13 to 16 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="0.50"/>
                    <measurement group_id="B2" value="10.2" spread="1.03"/>
                    <measurement group_id="B3" value="14.8" spread="1.03"/>
                    <measurement group_id="B4" value="11.2" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116.7" spread="9.01"/>
                    <measurement group_id="B2" value="151.8" spread="9.44"/>
                    <measurement group_id="B3" value="165.5" spread="9.74"/>
                    <measurement group_id="B4" value="151.6" spread="19.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" spread="16.31"/>
                    <measurement group_id="B2" value="70.3" spread="20.53"/>
                    <measurement group_id="B3" value="86.3" spread="29.50"/>
                    <measurement group_id="B4" value="70.6" spread="30.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)</title>
        <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
        <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>6-12 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>13-16 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)</title>
          <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
          <units>ng/mL*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7874" spread="2913"/>
                    <measurement group_id="O2" value="5851" spread="2083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>For Olmesartan, Area Under the Concentration-time Curve From the Time of the Dose to Infinity</title>
        <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
        <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>6-12 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>13-16 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>For Olmesartan, Area Under the Concentration-time Curve From the Time of the Dose to Infinity</title>
          <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
          <units>ng/mL*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7988" spread="2913"/>
                    <measurement group_id="O2" value="5982" spread="2130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>For Olmesartan, the Elimination Constant Rate</title>
        <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
        <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>6-12 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>13-16 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>For Olmesartan, the Elimination Constant Rate</title>
          <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.090" spread="0.029"/>
                    <measurement group_id="O2" value="0.079" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>For Olmesartan, the Maximum Plasma Concentration Over the Entire Sampling Phase</title>
        <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
        <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>6-12 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>13-16 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>For Olmesartan, the Maximum Plasma Concentration Over the Entire Sampling Phase</title>
          <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1227" spread="451"/>
                    <measurement group_id="O2" value="895" spread="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Foe Olmesartan, the Time of Maximum Plasma Concentration</title>
        <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
        <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>6-12 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>13-16 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Foe Olmesartan, the Time of Maximum Plasma Concentration</title>
          <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.3"/>
                    <measurement group_id="O2" value="2.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>For Olmesartan, the Elimination Half-life of the Drug in Plasma</title>
        <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
        <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>6-12 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>13-16 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>For Olmesartan, the Elimination Half-life of the Drug in Plasma</title>
          <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="2.4"/>
                    <measurement group_id="O2" value="9.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>For Olmesartan, the Apparent Oral Clearance</title>
        <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
        <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>6-12 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>13-16 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>For Olmesartan, the Apparent Oral Clearance</title>
          <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.9"/>
                    <measurement group_id="O2" value="6.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>For Olmesartan, the Apparent Oral Volume of Distribution</title>
        <time_frame>PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing</time_frame>
        <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>6-12 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
          <group group_id="O2">
            <title>13-16 Years of Age Olmesartan Group</title>
            <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>For Olmesartan, the Apparent Oral Volume of Distribution</title>
          <population>24 participants were enrolled; however, the data for the four 2-5 years old participants were not analyzed.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="20.7"/>
                    <measurement group_id="O2" value="81.3" spread="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>&lt;3 days</time_frame>
      <desc>Adverse events observed by the Investigator, or reported by the subject, and any remedial action taken, were recorded in the CRF by the Investigator. The nature of each event, time of onset after drug administration, duration, and intensity were documented together with the Investigatorâ€™s opinion of the causal relationship to the treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olmesartan Group - 2 to 5 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
        <group group_id="E2">
          <title>Olmesartan Group - 6 to 12 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
        <group group_id="E3">
          <title>Olmesartan Group - 13 to 16 Years Old</title>
          <description>Hypertensive children and adolescents of both genders between the ages of 2 years and 16 years of age. The dose for children &lt;6 years old was 0.3 mg.kg; the dose for children &gt; or = to 6 years of age and &gt; or = to 35 kg was 40mg; for &lt;35 kg the dose was 20 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abnormal urine analysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Kessler</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>732-590-5032</phone>
      <email>hmkessler@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

